Effectiveness of maintenance treatments for nonsmall cell lung cancer

References

• JemalASiegelRJiaquanXWardECancer Statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• AzzoliCGBakerSJrTeminSAmerican Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small cell lung cancerJ Clin Oncol200927366251626619917871
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• EttingerDSAkerleyWBeplerGNon-small cell lung cancerJ Natl Compr Canc Netw20108774080120679538
   PubMed Web of Science ®Google Scholar
• StinchcombeTESocinskiMAMaintenance therapy in advanced non-small cell lung cancer: current status and future implicationsJ Thorac Oncol20116117418221127437
   PubMed Web of Science ®Google Scholar
• FidiasPNovelloSStrategies for prolonged therapy in patients with advanced non-small-cell lung cancerJ Clin Oncol201028345116512321041704
   PubMed Web of Science ®Google Scholar
• GalettaDRossiAPiscontiSMillakuAColucciGMaintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the questionCancer Treat Rev201036Suppl 3S30S3321129607
   PubMed Web of Science ®Google Scholar
• SoonYYStocklerMRAskieLMBoyerMJDuration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trialsJ Clin Oncol200927203277328319470938
   PubMed Web of Science ®Google Scholar
• PatelJDHensingTARademakerAPhase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancerJ Clin Oncol200927203284328919433684
   PubMed Web of Science ®Google Scholar
• BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer200652215516316569462
   PubMed Web of Science ®Google Scholar
• PerolMChouaidCMilleronBJMaintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III studyJ Clin Oncol201028Suppl 15 Abstr 7507
   Web of Science ®Google Scholar
• BelaniCPWaterhouseDMGhazalHPhase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol20102815 Suppl Abstr 7506
   Google Scholar
• BelaniCPBarstisJPerryMCMulticenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observationJ Clin Oncol200321152933293912885812
   PubMed Web of Science ®Google Scholar
• BrabenderJDanenbergKDMetzgerREpidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survivalClin Cancer Res2001771850185511448895
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMBunnPAJrEpidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol200321203798380712953099
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerNEJM20062552425422550
   Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiLJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL)Ann Oncol20102191804180920150572
   PubMed Web of Science ®Google Scholar
• WesteelVQuoixEMoro-SibilotDRandomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancerJ Natl Cancer Inst200597749950615812075
   PubMedGoogle Scholar
• FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol200927459159819075278
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet200937496991432144019767093
   PubMed Web of Science ®Google Scholar
• TakedaKHidaHSatoTRandomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)J Clin Oncol201028575376020038730
   PubMed Web of Science ®Google Scholar
• GaafarRMSurmontVScagliottiGA double-bind, randomized, placebo-controlled phase III study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03)J Clin Oncol20102815 Suppl Abstr 7518
   Google Scholar
• KellyKChanskyKGasparLEPhase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023J Clin Oncol200826152450245618378568
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet201011652152920493771
   PubMed Web of Science ®Google Scholar
• KabbinanvarFFMillerVAJohnsonBEOverall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol201028Suppl 15 Abstr 7526
   Web of Science ®Google Scholar
• KleinRWielageRMuehlenbeinCCost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancerJ Thorac Oncol2010581263127220581708
   PubMed Web of Science ®Google Scholar
• JoergerMMatter-WalstraKFruhMAddition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: A cost-utility analysisAnn Oncol201122356757420843984
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• YangCHYuCJShihJYSpecific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naïve non-small-cell lung cancer receiving first-line gefitinib monotherapyJ Clin Oncol200826162745275318509184
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• MokTSWuYThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar